AbbVie Sets Biosimilar Expectations As It Prepares To Take The Plunge On Humira
US Brand Erosion Expected To Be 37% In 2023; Amgen Adalimumab Pricing ‘Not A Surprise’
• By David Wallace
AbbVie is preparing for a sharp drop in Humira revenues • Source: Shutterstock 
